Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alger Weatherbie Specialized Growth Fund H. George Dai, Joshua D. Bennett | “NeoGenomics remains the leading pure-play provider of specialty oncology lab testing services, serving hospitals, oncologists, and pathologists. We believe the company's competitive advantage stems from its extensive testing menu, ability to serve as a comprehensive one-stop solution, strong commercial presence, trusted reputation among pathologists, and nationwide laboratory network. Shares detracted from performance after the company reported slightly weaker-than-expected revenues, although it exceeded consensus estimates for earnings before interest, taxes, depreciation, and amortization (EBITDA). Management noted that the revenue shortfall was primarily attributed to weakness in non-clinical segments, such as pharma services, reflecting broader cyclical pressures from reduced funding in the biopharma industry. Nevertheless, the company reaffirmed its full-year 2025 organic revenue guidance, while total revenue guidance was slightly increased to reflect a recent acquisition. BSD Analysis: NeoGenomics is emerging from years of operational chaos with a stronger diagnostic platform, tighter cost structure, and a clear path back to growth. Oncology testing volumes are rebounding, pharma services remain a high-margin engine, and new leadership is finally restoring discipline. The company sits at the intersection of precision medicine, companion diagnostics, and cancer screening — secular growth tailwinds the market is barely valuing. NeoGenomics isn't fully out of the woods, but the turnaround is real and accelerating.” | BULL | Q2 2025 Jul 7, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
